Who Paid My Doc
Tariq Waseem
General Practice Brooklyn, NY Medical Doctor
NPI 1366517930 CMS profile 106937
6010 Bay Pkwy, Ste 901, Brooklyn, NY 11204
General payments
$196
Research payments
$0
Ownership & investment interest
$0
Through program year 2021, Tariq Waseem of Brooklyn, NY is reported in the CMS Open Payments database as having received $196 across 7 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 49th percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2021 | General | $99 | 1 | |
| 2020 | General | $43 | 3 | |
| 2019 | General | $54 | 3 |
Beside peers
- Tariq Waseem
- General Practice median
- Middle half of General Practice
- National median
In program year 2025, general payments to Tariq Waseem were reported at $0. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.
Show as a table
| Year | Tariq Waseem | General Practice median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $54 | $107 | $37–$285 | $163 |
| 2020 | $43 | $75 | $25–$213 | $114 |
| 2021 | $99 | $93 | $30–$272 | $132 |
| 2022 | $0 | $103 | $36–$279 | $149 |
| 2023 | $0 | $106 | $34–$276 | $160 |
| 2024 | $0 | $114 | $39–$290 | $164 |
| 2025 | $0 | $106 | $35–$292 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 99 drugsPart D claims
4,979
Drug cost
$384,798
Branded share of claims
18.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 138 | $133,974 | |
| Januvia Sitagliptin Phosphate | Brand | 61 | $56,641 | |
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | Brand | 14 | $55,489 | |
| Xarelto Rivaroxaban | Brand | 25 | $20,948 | |
| Jardiance Empagliflozin | Brand | 21 | $16,392 | |
| Breo Ellipta Fluticasone/Vilanterol | Brand | 35 | $15,587 | |
| Trulicity Dulaglutide | Brand | 15 | $15,513 | |
| Lumigan Bimatoprost | Brand | 18 | $6,874 | |
| Incruse Ellipta Umeclidinium Bromide | Brand | 13 | $4,373 | |
| Combigan Brimonidine Tartrate/Timolol | Brand | 16 | $3,598 |
The 10 drugs with the highest cost, of 99 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,210 Part D prescribers listed as General Practice; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 36 billing codesPaid by Medicare
$60,794
Medicare patients
217
Services billed
832
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Alzheimer's or dementia | 65% | |
| Diabetes | 59% | |
| Heart failure | 43% | |
| Depression | 39% | |
| Ischemic heart disease | 36% | |
| Chronic kidney disease | 31% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
7 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
General Practice in New York
Practitioners in the same specialty and state, ranked by reported value.
All General Practice
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.